Hourly refreshMon, Sep 21, 2026

Press Release Database

Recent press releases, indexed by topic.
Topic

Healthcare

7,746 press releases indexed under healthcare.

AllFinanceCryptoAISaaSHealthcareReal EstateEnergyRetailAutomotiveGamingMediaEducation
DownloadExcelTXT
Finance · Healthcare

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

MAINZ, Germany, and ROCKVILLE, USA, September 14, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”) today announced the first median overall survival (“OS”) data from the non-pivotal stage 1 of the global randomized PRESERVE-003 Phase 3 clinical trial ( NCT05671510 ) of gotistobart (also known as BNT316 or ONC-392), in patients with squamous non-small lung cancer (“NSCLC”) whose disease progressed on prior immunotherapy and chemotherapy. Gotistobart is an investigational CTLA-4-targeting immunotherapy designed to selectively deplete regulatory T cells (“Tregs”) within the tumor microenvironment and restore anti-tumor immune activity.

Sep 14 · 08:00GlobeNewswire
Healthcare

Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture

Novo Nordisk will mark the beginning of its next chapter by unveiling a rebrand centred on ‘Lasting Health Starts Now’, and the single ‘Novo’ name ...

Sep 14 · 07:05GlobeNewswire
Healthcare

Isolated Communities Overcome Severe Staffing Scarcity Through Local Mentorship as Daniels Memorial Healthcare Center Joins "All Access hosted by Andy Garcia"

An upcoming educational feature explores the critical intersection of community-driven workforce programs and modern rural hospital sustainability. LOS ANGELES, Sept. 14, 2026 /PRNewswire/ -- The educational series "All Access hosted by Andy Garcia" will document a compelling solution to...

Sep 14 · 07:00PR Newswire
Healthcare

Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO

CHENGDU, China, Sept. 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational study of its novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug...

Sep 14 · 06:18PR Newswire
Finance · SaaS

Physitrack Selected by US Metropolitan Healthcare System for Enterprise-Wide, ...

(PR-inside.com) Three-year enterprise agreement with a total three year contract value of approximately US$78,000 (approximately EUR 67,000) in total, covering an enterprise-wide deployment and full Epic and MyChart integration. LONDON, GB / ACCESS Newswire / September 14, 2026 / Physitrack PLC (STO:PTRK), a global provider of digital health and wellbeing technology, today announces that it has been selected as the digital rehabilitation platform for a US metropolitan safety net healthcare system, following a competitive selection process. The agreement covers a three-year relationship with a break option after the second year. It represents annual recurring revenue of approximately US$26,500 (approximately EUR 22,800) in the ..

Sep 14 · 06:00PR-Inside
Healthcare

Tomonari Abe, President of Abe Yoando Pharma, Selected as First Japanese Speaker at Longevity Investors Conference 2026 in Switzerland

- Head of 295-year-old Japanese Pharmaceutical Pioneer to Present Asia's Longevity Growth Strategies and Bioscientific Research Initiatives at Prestigious Conference - TOKYO and GSTAAD, Switzerland, Sept. 14, 2026 /PRNewswire/ -- Abe Yoando Pharma Co., Ltd., a nearly 300-year-old...

Sep 14 · 06:00PR Newswire
Healthcare

Elder Care Launches Mobile App to Digitize Medical Paperwork for Family Caregivers

Elder Care has released a mobile application that allows family caregivers to photograph and store medical documents from doctors and hospitals, providing centralized access for authorized family members.

Sep 14 · 05:40PressReleaseNews
Healthcare

Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients

Allschwil, Switzerland, September 14, 2026

Sep 14 · 05:15GlobeNewswire
Healthcare

Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

SHANGHAI and HONG KONG, Sept. 14, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for...

Sep 14 · 04:26PR Newswire
Healthcare

Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8% SEOUL, South Korea, Sept. 13, 2026...

Sep 14 · 01:45PR Newswire
Finance · Healthcare

Pomerantz LLP Files Class Action Lawsuit Against Fractyl Health, Inc. ...

(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 13, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations ..

Sep 13 · 22:02PR-Inside
Finance · Healthcare

Pomerantz LLP Moves to File Class Action Litigation Against Fractyl ...

(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 13, 2026 / Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. ("Fractyl" or the "Company") (NASDAQ:GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations ..

Sep 13 · 15:01PR-Inside
← Prev123646Next →